Nasdaq

Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR)

Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...
Seeking Alpha

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Medscape

FDA Approves Once-Monthly Cholesterol-Lowering Evolocumab (Repatha) Device

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...
Becker's Hospital Review

FDA approves single-dose monthly injector for cholesterol drug

Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug. The device, created in conjunction with ...
Seeking Alpha

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...